RxDoctor Payments Data

Megan Blatz

Nurse Practitioner · Doylestown, PANPI 1962719435

Payments from drug & device makers

$3,476in general payments, 2019–2025

Across 86 payments — averaging $40.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Boston Scientific$110
  • AbbVie$103
  • Olympus America Inc.$84
  • Astellas Pharma US Inc$78
  • Convatec Inc.$56
  • plus $274 from 9 others

What the payments were for

  • Food & beverage$3,476100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,476 in reported general payments places this provider in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$92,755
Medicare patients
326
Services billed
1,694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron174$110,096
MyrbetriqMirabegron145$91,202
Estradiol316$18,107
Methenamine Hippurate92$5,768
Solifenacin Succinate89$1,930
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst164$1,336
Amitriptyline Hcl96$1,183
Nortriptyline Hcl13$392
Fluconazole43$250
Hydroxyzine Hcl20$249
Clobetasol Propionate13$196
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim89$185
Diazepam27$183
Cephalexin13$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$26$110,096174 claims
Astellas Pharma US IncMyrbetriq$78$91,202145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Doylestown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →